After being fired, I became the light of medicine

Chapter 96 Leader
The first person to speak was Chen Wen, director of the Department of Infectious Diseases.

He is the initiator and moderator of this multi-departmental seminar.

As soon as he finished speaking, a key doctor from the hepatobiliary surgery department raised his hand and said:

"First of all, we must make it clear that hepatitis B and cirrhosis are two different diseases."

"Long-term chronic hepatitis B can lead to cirrhosis, but cirrhosis is not only caused by hepatitis B; severe fatty liver and alcoholic liver can lead to long-term inflammation of liver cells and eventually induce cirrhosis."

"Liver cirrhosis is a pathological structural change that cannot be reversed."

"So, my suggestion is that patients with cirrhosis in the 'decompensated stage' do not need to try it. 'Decompensated stage' means that the liver function is reduced to less than 50%.

If 'Abrocitinib' is used at this time, its hepatotoxicity will damage the liver again, which is likely to reduce the patient's survival time, which is not worth the loss."

The doctors present nodded.

Moreover, there is one thing this key doctor did not make clear.

Patients with decompensated cirrhosis are almost in the final stage, and "Afovir" has serious side effects. If someone dies while taking the medicine, neither the hospital nor the doctor can bear the responsibility.

"I agree with Dr. Zhang. If we want to try using 'Afovir' on patients with liver cirrhosis, it should be used at most in the compensatory stage."

"However, the function of the compensated liver is only about 70% of that of a normal liver. To put it bluntly, it is just one step away from the decompensated stage. Will the hepatotoxicity of 'Afovir' directly cause the patient to enter the 'decompensated stage'?"

"Of course, I think that completely curing hepatitis B will still be beneficial to patients with cirrhosis. It is very likely that the condition of patients with cirrhosis will not deteriorate any further, allowing them to survive for a long time..."

"Overall, I think this risk is worth taking and worth trying."

The seminar unfolded quietly, and doctors from different departments expressed their own opinions. After heated discussions, the treatment plan of using "Afovir" on patients with compensated cirrhosis was recognized by the vast majority.

Gradually, the topic of discussion turned to how to reduce the side effects of drugs and reduce liver damage in patients.

"My suggestion is to try combined treatment."

"First, take 'tenofovir alafenamide' to reduce the amount of hepatitis B virus in the patient's body, and then take 'afovir', and inject liver-protecting drugs at the same time to minimize the damage of 'afovir' to the liver."

"However, we still need to try in clinical practice which liver-protecting drugs are most effective, what dosage to use, and whether the combination with 'Avofovir' will produce adverse reactions."

The doctor present nodded slightly.

"Icofenac" is a new drug and there is no precedent for its combination use in clinical practice. Everything must be explored with caution.

And this is the greatest thing about clinical medicine, or rather, the greatest thing about clinicians.

Pharmaceutical companies have almost completed their mission after producing a drug, while clinicians need to consider how to better utilize the drug and develop various combination treatment plans to provide better treatment for patients.

The seminar was gradually coming to an end, and two combined treatment plans were preliminarily determined. Just as Chen Wen was about to end the meeting, Dr. Zhang, who spoke at the beginning, suddenly raised his hand and said:
"Director Chen, I have another suggestion."

"The key point now is to reduce the damage to the liver caused by the side effects of 'Afovir'. In this case, I think we can contact Qingshan Pharmaceutical to see if we can invite them in."

"After all, 'Ekofovir' was developed by them. They know its pharmaceutical toxicity and rejection better than we do, so we can ask them to guide us in the use of the drug."

As soon as the words fell, everyone's eyes lit up, and even Chen Wen nodded slightly.

Although pharmaceutical companies generally do not participate in the clinical treatment of drugs, everyone knows that Zhang Yang, the CEO of Qingshan Pharmaceutical, has a good relationship with President Zhou...

After thinking for a moment, Chen Wen agreed: "I will report this matter to President Zhou. If we can invite Qingshan Pharmaceutical to join us, it will undoubtedly make us more confident in using the medicine."

"Okay, thank you all for your hard work. Today's seminar ends here."

Chen Wen acted quickly. After the R&D meeting ended, he immediately split his forces into two groups.

On the one hand, we began to arrange for doctors in the department to communicate with compensated cirrhosis patients about the treatment plan of "Afovir" and explain the risks of medication;

On the other hand, we are contacting Tsingshan Pharmaceutical, hoping that it can also participate.

The next day, Zhang Yang received an invitation from the Infectious Diseases Department of the Third People's Hospital.

In the office, Wei Tian was reporting to Zhang Yang.

"Mr. Zhang, this is roughly the situation. They are planning to use Ekfovir on patients with liver cirrhosis and have invited us to be their technical consultant."

"How do you respond? I think we are going to do a Phase IV clinical trial anyway, so we can participate in it."

Phase IV clinical trials refer to the period after a new drug is launched on the market, when pharmaceutical companies continue to examine the efficacy and adverse reactions of the new drug under conditions of widespread use.

and evaluating the risks of use in special populations and improving dosing.

Of course, because Phase IV clinical trials are not like Phases I, II, and III clinical trials that determine drug marketing, most pharmaceutical companies progress very slowly or even stagnate during Phase IV clinical trials.

But this is not what Zhang Yang is concerned about.

He thought of the "hepatocyte regeneration activator" obtained in the system.

Actually,
After the overall situation of "Ekofovir" was settled, he slightly modified the relevant drug ingredients and activators of this "liver cell activator" drug and handed it to Wei Tian.

Wei Tian didn't have any doubts.

When Zhang Yang led the research and development team to demonstrate amazing capabilities in "Acofenac", he was completely convinced. In his eyes, Mr. Zhang Yang is a true genius.

This may sound "fantasy", but those who have actually participated in front-line scientific research know that whether it is a national aerospace project or chip development in the commercial field;

Or the various key projects of major universities, the biopharmaceuticals of pharmaceutical companies,

99% of the decision on whether a project can be successful depends on the project leader, that is, the top one or two geniuses.

The other 95% of the R&D team are just there to help...

It may not be quite accurate to say that they are just there to watch the show. After all, those who can participate in major projects are high-end talents in the industry. But compared to the irreplaceability of the leaders, there are many people who can replace high-end talents.

For example, although Zhang Yang did a good job at Beifeng Pharmaceutical before, most of the work was completed under the work framework set by the leader. If he can do it, other talented people with work experience can also do it.

Therefore,
When Wei Tian heard Zhang Yang say that this "liver cell activator" was discovered accidentally during the development of "Ekofovir",
After finding out that it was an activator that could potentially regenerate liver cells, he immediately mobilized a research and development team to conduct further research on Zhang Yang's discovery.

This is the role of a leader.

Thinking of this, Zhang Yang thought back to the invitation from the Third People's Hospital. After a little thought, he said:

"How about this, since I'm free today, come with me to the Three Men Hospital."

(End of this chapter)